Harlan Laboratories Contract Research Services (CRS) and Ipsen have strengthened their collaboration with a new business agreement. The companies have entered into a three-year program to develop early preclinical stage drug candidates, with exclusivity in some specific areas.

“This new agreement with Ipsen is in line with our strategy to satisfy the needs of the pharmaceutical industry in the preclinical arena and underlines our willingness to be close to our customers, helping them to make their drug candidates successful,” said Dr. Ciriaco Maraschiello, head of Global General Toxicology, Harlan Laboratories CRS. “We are delighted to be working with Ipsen and believe this collaboration will offer clients an unrivalled level of expertise and support in the early development of new drug formulations. This is a very important agreement which highlights our commitment to the Pharma sector and reinforces our presence in the drug discovery segment of the drug development process.”